Boardroom Alpha
Meeting calendar
ACH · Special meeting · Tuesday, December 1, 2026

Accendra Health Inc

7 nominees · 2 ballot items.

Shareholders will vote on a discretionary 1-for-20 to 1-for-30 reverse stock split with a corresponding reduction in authorized common shares, and on adjournment of the Special Meeting to solicit additional proxies if needed.

Market cap
—
1Y TSR
-93.7%
Board grade
C-
Record date
Oct 27, 2026
Filing
DEF 14A
Filed Oct 29, 2026 · DEF 14A
Proposals

On the ballot2

  1. 1

    The Reverse Split Proposal

    ManagementBoard: FOR

    Approve an amendment to the Company’s Amended and Restated Articles of Incorporation authorizing the Board, at its discretion, to effect a 1-for-20 to 1-for-30 reverse stock split of the Common Stock, with the final ratio selected by the Board, and to reduce authorized Common Stock by the corresponding ratio. The stated purpose is principally to increase the per-share price and help regain compliance with the NYSE’s $1.00 minimum average closing price requirement.

    More detail

    The proposal asks shareholders to approve an amendment to the Articles of Incorporation permitting the Board to implement a reverse stock split at a ratio between 1-for-20 and 1-for-30. The Board would choose the final ratio and determine whether and when to implement the transaction after approval. Authorized Common Stock would be reduced proportionately, while the $2.00 par value would remain unchanged. The principal business rationale is to increase the market price of the Common Stock and regain compliance with the NYSE’s $1.00 minimum average closing price requirement. The Company received an NYSE non-compliance notice on October 6, 2026, and has a six-month cure period under the applicable listing rule. Failure to regain compliance could lead to delisting proceedings, reduced liquidity, penny-stock consequences, and greater difficulty raising capital. The filing also identifies potential benefits including broader institutional investor interest, improved marketability, and potentially lower price volatility. Conversely, the Company warns that the split may not increase the stock price, could reduce trading liquidity and market capitalization, create odd lots, and may be followed by significant volatility or a short squeeze. The Board unanimously recommends approval because it believes the transaction is a potentially effective means of addressing the NYSE deficiency and avoiding the adverse consequences of delisting.

  2. 2

    The Adjournment Proposal

    ManagementBoard: FOR

    Approve adjournment of the Special Meeting, if necessary or appropriate, to allow management to solicit additional proxies if there are insufficient votes to approve the Reverse Split Proposal.

    More detail

    The proposal asks shareholders to authorize adjournment of the Special Meeting if the Reverse Split Proposal lacks sufficient support. An approved adjournment would give management additional time to solicit proxies supporting the reverse stock split. The filing states that management could seek votes from shareholders who have not yet voted as well as attempt to persuade shareholders who previously voted against the reverse split to change their votes. The authority could be used even if proxies against the Reverse Split Proposal already appear sufficient to defeat it. The adjournment would therefore preserve the Company’s opportunity to obtain approval rather than requiring an immediate final vote on the reverse split. The proposal is procedural and does not itself implement a reverse stock split or amend the Articles of Incorporation. Its practical significance is tied to the Company’s NYSE minimum-price deficiency and the risk that failure to approve and implement a reverse split could result in delisting proceedings. Approval requires that votes cast for the proposal exceed votes cast against it, with abstentions and broker non-votes having no effect. The Board recommends voting FOR because additional solicitation time may help secure the votes needed for the Reverse Split Proposal.

Director elections

Nominees on the ballot7

Not independent
Tenure on this board
7.3 yrs
Also a director at
Idex Corp (IEX)
Ownership

Top institutional holders10

Latest 13F quarter
1PARADIGM CAPITAL MANAGEMENT INC/NY5.1%3,952,200$2M
2VANGUARD CAPITAL MANAGEMENT LLC4.0%3,087,931$2M
3BlackRock, Inc.3.9%3,022,919$2M
4BlackRock, Inc.2.5%1,898,066$1M
5Dana Investment Advisors, Inc.2.2%1,713,671$964K
6MARSHALL WACE, LLP2.1%1,652,241$925K
7BW Gestao de Investimentos Ltda.2.1%1,609,353$906K
8VANGUARD PORTFOLIO MANAGEMENT LLC2.1%1,604,690$903K
9STATE STREET CORP2.1%1,583,527$891K
10GEODE CAPITAL MANAGEMENT, LLC1.7%1,328,786$748K
Filings

Accendra Health Inc proxy statements and SEC reports

Annual & quarterly reports (10-K, 10-Q)
Proxy statements (DEF 14A)
Reference

Frequently asked questions

When is the Accendra Health Inc 2026 special meeting?
Accendra Health Inc (ACH) holds its 2026 special shareholder meeting on Tuesday, December 1, 2026.
What is the record date for the Accendra Health Inc 2026 meeting?
The record date for the Accendra Health Inc 2026 meeting is Tuesday, October 27, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Accendra Health Inc's 2026 meeting?
The board is presenting 7 director nominees at the Accendra Health Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Accendra Health Inc 2026 meeting?
Shareholders will vote on 2 proposals at the Accendra Health Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer